

Diorganotin(IV) Complexes with Methionine Methyl Ester. Equilibria and Displacement by DNA Constituents

M.M. Shoukry^{1,2,*} Ayser Al-Alousi² and Sameya M. Tarek

¹Department of Chemistry, Faculty of Science, Islamic University, Madina, Saudi Arabia.

²Department of Chemistry, Faculty of Science, Cairo University, Egypt.

Received 18 August 2013, revised 15 April 2014, accepted 29 April 2014.

ABSTRACT

The coordination of methionine methyl ester with dimethyltin(IV) (DMT), dibutyltin(IV) (DBT) and diphenyltin(IV) (DPT) was investigated at 25 °C and 0.1 mol dm⁻³ ionic strength in water for dimethyltin(IV) and in 50 % dioxane–water mixture for dibutyltin(IV) and diphenyltin(IV). Methionine methyl ester forms 1:1 and 1:2 complexes with diorganotin(IV). The corresponding formation constants were calculated by using the non-linear least-squares program MINQUAD-75. The concentration distribution of the various complex species was evaluated as a function of pH. The displacement of coordinated methionine methyl ester with some DNA constituents was calculated based on equilibrium aspects.

KEYWORDS

Dimethyltin(IV), dibutyltin(IV), diphenyltin(IV), methionine methyl ester, stability constant.

1. Introduction

A tremendous amount of research is directed towards the design of non-platinum chemotherapeutic agents with the aim to optimize the features of classical platinum drugs containing the basic cisplatin framework, *viz.* their toxic side effects, inherent intrinsic resistance and high cost.¹ Among the most noteworthy cases, organotin(IV) compounds have emerged as a promising class of cancer chemotherapeutics.

It has been well established that organotin(IV) compounds are very important in cancer chemotherapy because of their apoptotic inducing character.^{2,3} During the last few years it has been noticed that organotin(IV) compounds occupy an important place in cancer chemotherapy.^{4–7} Blower⁸ described thirty interesting inorganic pharmaceuticals, four of which are tin compounds. Numerous diorganotin(IV) derivatives have been found to exhibit high *in vivo* cytotoxicity against P388 lymphocytic leukaemia but to exhibit less or no activity against other murine systems.^{9–14} However, the new *in vitro* human tumour cell-screening tests have once again demonstrated the potential of organotin(IV) complexes, some of which have exhibited high activity¹⁵ and thus interest in them has been revitalized.

Organotin(IV) compounds are involved in cancer treatment *via* different mechanisms at the molecular level. The binding ability of organotin(IV) compounds towards DNA, the ultimate drug target, depends on the DNA structure. The phosphate groups of the DNA sugar backbone usually act as an anchoring site and binding at the nitrogens of the DNA bases is extremely effective, thus often resulting in the stabilization of the tin centre as an octahedral stable species.¹⁶ The antitumour activity of the coordination compounds R₂SnX₂L₂ is controlled by the nature of R, the leaving group (X) and the ligand (L). The coordinated ligand (L) favours in some way the transport of the drugs into cells, while the antitumour activity is exerted by the diorganotin(IV) moiety dissociated from the complex.¹⁷ The latter interacts with nucleic acids, similar to the widely used anticancer drug cisplatin. Therefore, there is a relationship between the stability

of the organotin(IV) compounds and their antitumour activity. In conjunction with our previous studies on organotin(IV) complexes,^{18–22} the present paper aims to study the complex formation equilibria of dimethyltin(IV), dibutyltin(IV) and diphenyltin(IV) with methionine methyl ester. The displacement of coordinated methionine methyl ester with DNA constituents is also investigated.

2. Experimental

Experimental Organotin(IV) compounds used were dimethyltin(IV) dichloride (DMT), dibutyltin(IV) dichloride (DBT) and diphenyltin(IV) dichloride (DPT) obtained from Sigma-Aldrich Chem. Co. Methionine methyl ester hydrochloride and sodium nitrate were obtained from Acros Organics. Carbonate-free NaOH (titrant) was prepared and standardized against potassium hydrogen phthalate solution. The DMT solution was prepared in water, but the DBT and DPT solutions were prepared in dioxane due to their insolubility in water. The methionine methyl ester solution was prepared in water.

Potentiometric measurements were made by using a Metrohm 686 titroprocessor equipped with a 665 Dosimat (Switzerland). The titroprocessor and electrode were calibrated with standard buffer solutions, prepared according to NBS specifications.²³ The titrations were carried out in a purified N₂ atmosphere by using a previously described titration vessel.²⁴ The temperature was maintained constant by a Colora ultrathermostat. The protonation constants of methionine methyl ester hydrochloride were determined by titrating a 40 cm³ aliquot of 2.5 × 10⁻³ mol dm⁻³ methionine methyl ester hydrochloride solution. The hydrolysis constants of DMT, DBT and DPT were determined by titrating 40 cm³ aliquots of 2.5 × 10⁻³ mol dm⁻³ solutions of each substance. The formation constants of the organotin(IV) complexes were determined by titrating 40 cm³ of a solution containing methionine methyl ester hydrochloride (2.5 × 10⁻³ mol dm⁻³) and organotin(IV) with a concentration of 1.25 × 10⁻³ mol dm⁻³. The titration was performed at 25 °C in water for DMT but in 50 % dioxane–water solution for DBT and DPT. The ionic strength

* To whom correspondence should be addressed. E-mail: shoukrymm@hotmail.com

was 0.1 mol dm⁻³, adjusted with NaNO₃. The pK_w in dioxane–water solution was determined as described previously.^{22,25} For this purpose, various amounts of a standard NaOH solution were added to a solution containing 0.1 mol dm⁻³ NaNO₃ solution. The [OH⁻] was calculated from the amount of base added. The [H⁺] was calculated from the pH value. The product of [OH⁻] and [H⁺] was taken. The mean value of pK_w obtained in this way was 15.46 for 50 % dioxane–water solution. The equilibrium constants were evaluated from the titration data, defined by Eq. (1) and Eq. (2).



$$\beta_{pqr} = \frac{[M_pL_qH_r]}{[M]^p[L]^q[H]^r} \quad (2)$$

where M, L and H represent organotin(IV), methionine methyl ester and proton respectively and p, q and r are their stoichiometric coefficients, respectively. The calculations were performed by using the computer program MINQUAD-75.²⁶ The stoichiometries and stability constants of the complexes formed were determined by trying various possible composition models. The model finally selected was the one that gave the best statistical fit and was chemically consistent with the titration data without giving any systematic drifts in the magnitudes of various residuals, as described elsewhere.²⁶ Table 1 lists the formation constants together with their standard deviations as obtained from the program MINQUAD-75. The concentration distribution diagrams were obtained by using the program SPECIES.²⁷

3. Results and Discussion

The acid-base equilibria of methionine methyl ester were investigated under the same conditions used to study the organotin(IV) complexes. The hydrolysis of the dimethyltin(IV) cation in aqueous solution has been studied by several research groups.^{28–32} The potentiometric data were fitted by considering the formation of the species 10-1, 10-2, 10-3, 10-4 and 20-2


Table 1 Formation constants of organotin(IV) complexes with methionine methyl ester at 25 °C and 0.1 mol dm⁻³ ionic strength.

Organotin(IV)	p q r ^a	logβ (S.D.) ^b
DMT	0 1 1	7.11 (0.01)
	1 0 -1	-3.39 (0.01)
	1 0 -2	-8.99 (0.01)
	1 0 -3	-19.83 (0.01)
	1 0 -4	-31.30 (0.01)
	2 0 -2	-3.92 (0.01)
	1 1 0	9.62 (0.01)
	1 2 0	18.14 (0.06)
	1 1 -1	5.01 (0.02)
	DBT	0 1 1
1 0 -1		-4.39 (0.01)
1 0 -2		-15.06 (0.01)
2 0 -1		-1.41 (0.4)
1 1 0		6.3 (0.04)
1 2 0		12.71 (0.01)
1 1 -1		1.60 (0.1)
DPT	0 1 1	6.66 (0–0.01)
	1 0 -1	-2.82 (0.01)
	1 0 2	-13.58 (0.01)
	2 0 -1	2.07 (0.01)
	1 1 0	8.3 (0.06)
	1 2 0	14.11 (0.03)
	1 1 -1	3.2 (0.2)

^ap, q and r are the stoichiometric coefficients of dimethyltin(II), methionine methyl ester and proton, respectively.

^bS.D. – standard deviation.

(Table 1). The dimerizing ability of the aqua-hydroxo complexes is described by the general equilibrium (Eq. 3):



The dimerization constants can be determined³³ by (Eq. 4):

$$\log K_D = (\log \beta_{20-2}) - 2(\log \beta_{10-1})$$

$$= (-3.92) - 2(-3.39) = 2.86 \quad (4)$$

The potentiometric titration curves of methionine methyl ester in the presence and absence of diorganotin(IV) were compared. The complex titration curve was found to be significantly lower than the methionine methyl ester curve. This corresponds to the formation of a complex species through release of a hydrogen ion.

The complex formation equilibria of dimethyltin(IV) with methionine methyl ester were characterized by fitting the potentiometric data to various models. The best model was found to be consistent with the formation of the complexes with stoichiometric coefficients (110), (120) and (11-1).


The pK_a of the coordinated water molecule was calculated³⁴ by Eq. 5:

$$pK_a = \log \beta_{110} - \log \beta_{11-1} \quad (5)$$

The calculated values are 4.61, 4.70 and 5.10 for the dimethyltin(IV), dibutyltin(IV) and diphenyltin(IV) complexes, respectively. These values are higher than those of a water molecule coordinated to the corresponding free organotin(IV) ion. This may be due to the elongation of the Sn(IV)–H₂O bond caused by the coordination of methionine methyl ester.

The concentration distribution diagram (Fig. 1) shows that the species 110 is formed at low pH and is predominant at pH 3.4 with a degree of formation of 47 %. After pH 4.0 the monohydroxy species (11-1) and the hydrolyzed species (10-2) start to form and reach the formation percentage of 50 % at pH 8 and pH 8.5, respectively. The hydrolyzed species (10-3) is predominant after pH 11.

The hydrolysis of dibutyltin(IV) and diphenyltin(IV) ions was investigated in 50 % dioxane–water solutions. The potentiometric data was fitted considering the formation of the species (10-1), (10-2) and (20-1). The monohydroxo-bridged dimer (20-1) is assumed to form through dimerization of the tin(IV) *via* a hydroxo group, as given in Eq. 6.



where R is either a butyl- or phenyl- group.

The equilibrium constant for dimerization reaction (6) can be calculated from Eq. (7)³³ and amounts to 2.98 for dibutyltin(IV) and 4.89 for diphenyltin(IV).

$$\log K_{\text{dimer}} = \log \beta_{20-1} - \log \beta_{10-1} \quad (7)$$

The formation of the dihydroxo-bridged dimer (20-2), found for dimethyltin(IV) is not favoured in the case of diphenyltin(IV) and dibutyltin(IV) ions. This may be accounted for on the basis of a steric interaction effect between the bulky butyl groups in case of dibutyltin(IV) and phenyl groups in case of diphenyltin(IV). This will cause the dimeric form (20-2) to be strained and consequently energetically not favoured.

The pK_a of coordinated water molecules in dibutyltin(IV) and diphenyltin(IV) determined in 50 % dioxane–water solution were compared. The pK_a value for diphenyltin(IV) is lower than that of dibutyltin(IV). This may be explained on the premise that




Figure 3 Concentration distribution of various species as a function of pH in the DPT-MME system (at a concentration of 1.25 mmol dm⁻³ for DPT and 2.5 mmol dm⁻³ for MME) at 25 °C.

The equilibrium constant for the displacement reaction is given by Eq. 11 and 12:

$$K_{eq} = \frac{[(CH_3)_2Sn(B)^+][A]}{[(CH_3)_2Sn(A)^{2+}][B^-]}$$

Substitution results in:

$$K_{eq} = \frac{\beta_{110}\{(CH_3)_2Sn(B)^+\}}{\beta_{110}\{(CH_3)_2Sn(A)^{2+}\}} \quad (11)$$

$$\log K_{eq} = \log \beta_{110}\{(CH_3)_2Sn(B)^+\} - \log \beta_{110}\{(CH_3)_2Sn(A)^{2+}\} \quad (12)$$

The values of $\log \beta_{110}$ for $[(CH_3)_2SnB]^+$ complexes, taken from literature²² are given in Table 2. The value of $\log \beta_{110}$ for $[(CH_3)_2Sn(A)]^{2+}$, taken from Table 1 is 9.62 at 25 °C. By substituting into Eq. 11, the equilibrium constant for the displacement of coordinated methionine methyl ester by DNA constituents are calculated and their values are given in Table 2. These values clearly indicate the ability of DNA to displace methionine methyl ester from its dimethyltin(IV) complex and to what extent the methionine methyl ester complex can interact with the DNA constituents, the main target in tumour chemotherapy. Comparison of the displacement constant values for the different DNA constituents reveals that the nucleotides IMP and GMP have the highest values. This can be explained on the basis of the different coulombic force of attraction between the dipositively charged diorganotin(IV) ion and IMP or GMP having extra negative charges on the phosphate group. The increase of the coulombic force of attraction between diorganotin(IV) and IMP or GMP will facilitate the release of the coordinated methionine methyl ester.

Table 2 Equilibrium constants for the displacement reaction of coordinated methionine methyl ester by DNA constituents at 25 °C and 0.1 mol dm⁻³ NaNO₃.

DNA	$\log \beta_{110}$	$\log K_{eq}$
Inosine	8.13	-1.49
Inosine-5 -monophosphate	11.90	2.28
Guanosine-5 -monophosphate	12.34	2.72
Adenine	10.01	0.39
Adenosine	4.41	-5.21
Adenosine-5 -monophosphate	6.07	-3.55
Uracil	9.34	-0.28
Thymine	9.61	-0.01
Thymidine	9.25	-0.37
Cytosine	4.44	-5.18
Cytidine	3.77	-5.85

4. Conclusion

The present investigation describes the complex formation equilibria of methionine methyl ester with dimethyltin(IV), dibutyltin(IV) and diphenyltin(IV) ions. The results show the formation of 1:1 and 1:2 complexes. The displacement reaction of methionine methyl ester coordinated to dimethyltin(IV) by DNA constituents was investigated. The results reveal to what extent DNA, the major target in tumour therapy, can displace the coordinated methionine methyl ester and interact with dimethyltin(IV). These data are expected to contribute to the chemistry of organotin(IV) compounds as potential antitumor agents.

References and Notes

- A. Kotsakis, D. Hatzidaki, L. Vamvakas, N. Vardakis, A. Kalykakis, V. Bozionelou, N. Androulakis, K. Kalbakis, Z. Saridaki, V. Georgoulas and S. Angelaki, *Anticancer Res.*, 2010, 3, 4335–4342.
- C. Pellerito, P.D. Agati, T. Fiore, C. Mansueto, V. Mansueto, G. Stocco, L. Nagy and L. Pellerito, *J. Inorg. Biochem.*, 2005, 99, 1294–1305.
- F. Cima and L. Ballarin, *Appl. Organomet. Chem.*, 1999, 13, 697–703.
- M.N. Shuaibu, H. Kanbara, T. Yanagi, A. Ichinose, D.A. Ameh, J.J. Bonire and A.J. Nok, *Parasitolog. Res.*, 2003, 91, 5–11.
- C.R. Jan, B.P. Jiann, Y.C. Lu, H.T. Chang, W. Su, W.C. Chen, C.C. Yu and J.K. Huang, *Life Sci.*, 2002, 70, 1337–1345.
- M.P. Samuel, D. de Vos, D. Raveendra, J.A.R.P. Sarma and S. Roy, *Bioorg. Med. Chem. Lett.*, 2002, 12, 61–64.
- Khan, S.A.A. Nami and K.S. Siddiqi, *J. Organomet. Chem.*, 2008, 12, 1049–1057.
- P.J. Blower, *Annu. Rep. Prog. Chem., Sect. A*, 2004, 100, 633–658.
- M. Gielen and R. Willem, *Anticancer Drugs*, 1992, 12, 269–271.
- A.J. Crowe, in S.P. Fricker (Ed.), *Metal Compounds in Cancer Therapy*, Chapman and Hall, London, 1994, pp. 147–179.
- S.K. Hadjikakou and N. Hadjiliadis, *Coord. Chem. Rev.*, 2009, 253, 235–249.
- A.J. Crowe, P.J. Smith, C.J. Cardin, H.E. Parge and F.E. Smith, *Cancer Lett.*, 1984, 24, 45–48.
- M. Gielen, D. De Vos, A. Et-toubami, M. Boualam, A. Khloufi and R. Willem, *In Vivo*, 1993, 7, 171–174.
- A. Yahyi, A. El-touhami, R. Yahyaoui and R. Touzani, *Lett. Drug Des. Discov.*, 2010, 7, 534–540.
- M. Gielen, *Metal-Based Drugs*, 1994, 1, 213–219.
- S. Tabassum and C. Pettinari, *J. Organomet. Chem.*, 2006, 691, 1761–1766.
- N. Muhammad, A. Shah, Z. Rehman, S. Shuja, S. Ali, R. Qureshi, A. Meetsma and M.N. Nair, *J. Organomet. Chem.*, 2009, 694, 3431–3437.
- A.Sh. Al-Alousi, M.R. Shehata, M.M. Shoukry and N. Mahmoud, *Chem. Spec. Bioavailab.*, 2009, 21, 1–6.

- 19 A. Al-Najjar, M.M.A. Mohamed, M.R. Shehata and M.M. Shoukry, *Annali di Chim.*, 2006, **96**, 97–107.
- 20 A.A. Al-Najjar, M.M.A. Mohamed and M.M. Shoukry, *J. Coord. Chem.*, 2006, **59**, 193–206.
- 21 M.M.A. Mohamed, M.M. Shoukry, *Chem. & Pharm. Bull. (Japan)*, 2001, **49**, 253–257.
- 22 O. Al-Flaijj, M.R. Shehata, M.M.A. Mohamed and M.M. Shoukry, *Monatsh. Chem.*, 2001, **132**, 349–366.
- 23 R.G. Bates, *Determination of pH – Theory and Practice*, 2nd edn., Wiley Interscience, New York, 1975.
- 24 M.M. Shoukry, W.M. Hosny and M.M. Khalil, *Transition Met. Chem.*, 1995, **20**, 252–255.
- 25 R.J. Motekaitis, A.E. Martell and D.A. Nelson, *Inorg. Chem.*, 1984, **23**, 275–283.
- 26 P. Gans, A. Sabatini and A. Vacca, *Inorg. Chim. Acta*, **18**, 237 (1976).
- 27 L. Pettit, University of Leeds, U.K., personal communication.
- 28 G. Arena, R. Cali, A. Contino, A. Musumeci, S. Musumeci and R. Purrello, *Inorg. Chim. Acta*, 1995, **237**, 187–191.
- 29 T. Natsume, S. Aizawa, K. Hatano and S. Funahshi, *J. Chem. Soc. Dalton Trans.*, 1994, 2749–2753.
- 30 M.J. Hynes and J. O’Dowd, *J. Chem. Soc. Dalton Trans.*, 1987, 563–566.
- 31 C. De Stefano, C. Foti, A. Gianguzza, M. Martino, L. Pellerito and S. Sammartano, *J. Chem. Eng. Data*, 1996, **41**, 511–515.
- 32 C. Foti, A. Gianguzza, F.J. Millero and S. Sammartano, *Aquat. Geochem.*, 1999, **5**, 381–398.
- 33 T. Soldatovic, M. Shoukry, R. Puchta, Z.D. Bugarcic and R. van Eldik, *Eur. J. Inorg. Chem.*, 2009, 2261–2270.
- 34 M.R. Shehata, M.M. Shoukry, F.H. Abdel-Shakour and R. van Eldik, *Eur. J. Chem.*, 2009, 3912–3920.
- 35 L.C. Mun, M.A. Hapipah, S.K. Shin, A.S. Murestri and L.K. Mun, *Appl. Organomet. Chem.*, 2012, **26**, 310–319.